regenerative-medicine

UCL and Great Ormond Street Hospital scientists built a functional oesophagus from a donor scaffold and the recipient's own cells, restoring normal eating in eight pigs within six months.

ARPA-H has awarded up to $176.8 million to five teams building 3D-bioprinted kidneys and livers designed to work without immunosuppressive drugs, targeting first-in-human trials within five years.

Gene-edited pig kidneys have entered FDA-cleared clinical trials, a $176.8 million federal program is funding five teams to bioprint livers, and new cryopreservation methods could extend organ viability from hours to days.

Japan's health ministry has conditionally approved two iPS cell-derived drugs, marking the first time regenerative medicines built from induced pluripotent stem cells will reach patients commercially.